A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly

2007

Efficacy of Octreotide LAR in Treating Acromegaly

Sample size: 98 publication 10 minutes Evidence: moderate

Author Information

Author(s): Mercado Moises, Borges Fatima, Bouterfa Hakim, Chang Tien-Chun, Chervin Alberto, Farrall Andrew J, Patocs Attila, Petersenn Stephan, Podoba Jan, Safari Mitra, Wardlaw Joanna

Hypothesis

To evaluate the efficacy, safety and tolerability of octreotide LAR in the primary therapy of acromegaly.

Conclusion

Octreotide LAR is an effective alternative to surgery for treating acromegaly, leading to tumor shrinkage and improved biochemical control.

Supporting Evidence

72% of patients had a clinically relevant reduction in mean GH after 24 weeks.
44% of patients reached a GH level ≤ 2.5 µg/l after 48 weeks.
38% of patients normalized IGF-1 levels after 24 weeks.
63% of patients showed significant tumor volume reduction after 24 weeks.
Octreotide LAR treatment led to a consistent reduction in symptoms of acromegaly.

Takeaway

This study shows that a medicine called octreotide can help people with a condition called acromegaly by making their tumors smaller and helping them feel better.

Methodology

This was a prospective, open-label, multicentre study involving 98 previously untreated acromegaly patients who received octreotide LAR injections over 48 weeks.